课题基金 / 基金详情

Vaccine development for SARS-CoV2

Vaccine development for SARS-CoV2
SARS-CoV2 疫苗开发
批准号:
10260033
负责人:
NIKOLAI PETROVSKY
金额:
$50.0万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2014
资助国家:
美国
项目状态:
已结题
起止时间:
2014-09-30 至 2021-09-29

项目摘要

项目成果

NIKOLAI PETROVSKY的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The contractor will formulate a recombinant or nucleic-acid based SARS-CoV2 vaccine with their lead adjuvant, Advax-CpG and test the vaccine in multiple animal species for immunogenicity and efficacy, in preparation for a clinical trial scheduled to start in July 2020. In addition, the contractor will conduct in silico modeling studies of SARS-CoV2 spike protein-binding to the ACE2 receptor from a wide range of species to identify a) suitable animal models; b) identify potential intermediary host species; and c) assist in the search for antiviral drugs.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Adjuvant Development in the context of a vaccine to protect against tuberculosis
  • 批准号:
    10650130
  • 项目类别:
  • 资助金额:
    $155.2万
  • 财政年份:
    2018
  • 负责人:
    NIKOLAI PETROVSKY
  • 依托单位:
Adjuvant Development in the context of a vaccine to protect against tuberculosis
  • 批准号:
    10453430
  • 项目类别:
  • 资助金额:
    $117.05万
  • 财政年份:
    2018
  • 负责人:
    NIKOLAI PETROVSKY
  • 依托单位:
Adjuvant Development in the context of a vaccine to protect against tuberculosis
  • 批准号:
    10229328
  • 项目类别:
  • 资助金额:
    $147.32万
  • 财政年份:
    2018
  • 负责人:
    NIKOLAI PETROVSKY
  • 依托单位:
High-throughput screening for novel adjuvant discovery for vaccines against influenza virus
  • 批准号:
    9345559
  • 项目类别:
  • 资助金额:
    $40.0万
  • 财政年份:
    2014
  • 负责人:
    NIKOLAI PETROVSKY
  • 依托单位:
海外基金